Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc.
Your view on ZVRA
Overview
What the company does, where it operates, and who runs it.
About Zevra Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Neil F. McFarlane
- Headquarters
- 1180 Celebration Boulevard, Celebration, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Neil F. McFarlane
- Headquarters
- 1180 Celebration Boulevard, Celebration, FL, US
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).
The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial.
In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA.
The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Zevra Therapeutics, Inc. from FRC's valuation model, read against the market price. ZVRA last traded at $9.25, 7.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Zevra Therapeutics, Inc.. Starting points for Zevra Therapeutics, Inc.: P/E 7.2, EPS $1.31, beta 0.99 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Zevra Therapeutics, Inc.. Zevra Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Zevra Therapeutics, Inc.. Trailing twelve-month EPS for Zevra Therapeutics, Inc. stands at $1.31. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$24.60
average of 5 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy7
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.19 | $0.19 | $1.26 | $0.89 |
| Low estimate | $0.14 | $0.17 | $1.24 | $0.66 |
| High estimate | $0.24 | $0.21 | $1.29 | $1.11 |
| No. of analysts | 3 | 2 | 4 | 5 |
| Year-ago EPS | $0.211 | $0.601 | $1.351 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $40.21M | $38.98M | $153.70M | $176.51M |
| Low estimate | $39.36M | $36.37M | $152.79M | $164.54M |
| High estimate | $41.43M | $42.52M | $154.96M | $183.43M |
| No. of analysts | 6 | 3 | 7 | 7 |
| Year-ago revenue | $34.13M | $36.22M | $106.47M | — |
| Growth | +17.8% | +7.6% | +44.4% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Zevra Therapeutics, Inc.. Zevra Therapeutics, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALKSAlkermes plcDrug Manufacturers - Specialty & Generic$7.8B
- ANROAlto Neuroscience, Inc.Biotechnology$1.1B
- GHRSGH Research PLCBiotechnology$1.3B
- JAZZJazz Pharmaceuticals plcBiotechnology$15.4B
- MPLTMapLight Therapeutics, Inc.Biotechnology$294M
- NBIXNeurocrine Biosciences, Inc.Biotechnology$16.7B
- NMRANeumora Therapeutics, Inc. Common StockBiotechnology$69M
- PRAXPraxis Precision Medicines, Inc.Biotechnology$8.7B
More Biotechnology companies
- NTRBNutriband Inc.NASDAQ$71M
- NTRBWNutriband Inc.NASDAQ$77M
- NTRRNeutra Corp.OTC$291,790
- NURPFNeuren Pharmaceuticals LimitedOTC$1.1B
- NUVBNuvation Bio Inc.NYSE$1.4B
- NUZ.AXNeurizon Therapeutics LimitedASX
- NVAXNovavax, Inc.NASDAQ$1.3B
- NVCTNuvectis Pharma, Inc.NASDAQ$657M
- NWBONorthwest Biotherapeutics, Inc.OTC$359M
- NWPHFNewron Pharmaceuticals S.p.A.OTC$240M
- NXTCNextCure, Inc.NASDAQ$31M
- NYMXFNymox Pharmaceutical CorporationOTC$5M
ETFs holding Zevra Therapeutics, Inc.
% of the fund
- IWMiShares Russell 2000 ETF$76.6B in assets0.02%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF$1.0B in assets0.72%
- XPHState Street SPDR S&P Pharmaceuticals ETF$516M in assets1.36%
- FDLSInspire Fidelis Multi Factor ETF$255M in assets0.83%
- JSMLJanus Henderson Small Cap Growth Alpha ETF$379M in assets0.66%
- BFORBarron's 400SM ETF$238M in assets0.20%
- SFLOVictoryShares Small Cap Free Cash Flow ETF$887M in assets0.19%
Largest holders first, then the funds most concentrated in ZVRA.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Zevra Therapeutics, Inc., and how their positions are changing. At a $550.4M market value, institutional positions materially move Zevra Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Zevra Therapeutics, Inc. executives and directors. Shares of Zevra Therapeutics, Inc. have traded between $6.19 and $13.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Zevra Therapeutics, Inc.. Coverage tracks Zevra Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Zevra Therapeutics, Inc.